Search Results - "Militello, Anna Maria"
-
1
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review
Published in Frontiers in oncology (13-08-2019)“…Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline mutations is not yet fully elucidated…”
Get full text
Journal Article -
2
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma
Published in Journal of clinical oncology (01-02-2023)“…716 Background: Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) has a grim prognosis, with limited therapeutic options. In this context, treating patients…”
Get full text
Journal Article -
3
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Published in Cancer treatment reviews (01-11-2021)“…•Personalized treatments and predictive biomarkers of pancreatic cancer (PDAC) are still lacking.•BRCA1-2 alterations increase sensitivity to platinum salts…”
Get full text
Journal Article -
4
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients
Published in Cancer treatment reviews (01-03-2022)“…•BRCA1-2 mutations (gBRCA1-2) are responsible for PDAC in 15–20% of familiar cases.•gBRCA1-2 and DDR genes mutations (gDDR) emerged as therapeutic targets for…”
Get full text
Journal Article -
5
Prognostic role of a novel clinical-nutritional index in pancreatic ductal adenocarcinoma: The Pancreatic Adenocarcinoma Nutritional-Clinical Index (PANCIN)
Published in Journal of clinical oncology (01-02-2023)“…697 Background: Impaired nutritional status is often associated with Pancreatic Ductal Adenocarcinoma (PDAC) and poor prognosis. Little is known on the…”
Get full text
Journal Article -
6
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
Published in British journal of cancer (23-03-2023)“…Background Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information…”
Get full text
Journal Article -
7
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
Published in Cancer chemotherapy and pharmacology (01-12-2023)“…Purpose The clinical outcome and the efficacy of chemotherapy in pancreatic cancer patients with BRCA1/2 Variants of Unknown Significance (VUS) is unknown. We…”
Get full text
Journal Article -
8
-
9